αmβ2

αMβ2integrinagonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory properties (EC50=1.4 nM). It activates integrin-mediated cell adhesion and the JNK/ERK signaling pathway. Additionally, αMβ2integrinagonist-1 induces polarization of tumor-associated macrophages and enhances antitumor T-cell immune responses. This compound holds potential for research in cancer and chronic inflammatory diseases such as pancreatic cancer and rheumatoid arthritis.

Leukadherin-1 is an allosteric activator of CD11b/CD18. Increasing CD11b/CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendothelial migration; reduces inflammation.

S-methyl-KE-298 is the second main metabolite in plasma,is a methyl conjugate of deacetyl-KE-298.KE-298 inhibits matrix metalloproteinase (MMP-1) production from  rheumatoid arthritis (RA) synovial cells.

α4β1antagonist-1 (Compound 4) is a highly selective α4β1 integrin antagonist with an IC50 of 15 nM. It inhibits integrin-mediated cell adhesion and the activation of the ERK1/2 signaling pathway. α4β1antagonist-1 also exhibits partial agonist activity on αMβ2 integrin with an EC50 of 23 nM. This compound shows potential for research in chronic inflammatory diseases such as rheumatoid arthritis and multiple sclerosis, as well as in cancer.